PRCT
Procept Biorobotics Corp
17.90$
-0.1%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 46.2% | 51.2% | 43.8% | 41.0% | 36.8% | 36.0% | 36.1% | 36.7% | 37.1% | 39.4% | 35.1% | 34.0% | 36.3% | |
| 53.8% | 48.8% | 56.2% | 59.0% | 63.2% | 64.0% | 63.9% | 63.3% | 62.9% | 60.6% | 64.9% | 66.0% | 63.7% | |
| 33.0% | 33.3% | 29.4% | 32.8% | 28.5% | 22.1% | 23.7% | 20.3% | 19.9% | 24.9% | 25.8% | 21.3% | 22.9% | |
| 93.7% | 83.3% | 88.9% | 76.5% | 73.1% | 70.8% | 79.8% | 71.1% | 70.8% | 76.3% | 78.3% | 73.7% | 74.7% | |
| 126.7% | 116.6% | 118.3% | 109.3% | 101.7% | 92.9% | 103.5% | 91.4% | 90.7% | 101.3% | 104.1% | 95.0% | 97.6% | |
| -73.0% | -67.8% | -62.1% | -50.3% | -38.4% | -28.9% | -39.7% | -28.0% | -27.8% | -40.6% | -39.2% | -29.0% | -33.9% | |
| 2.9% | 2.6% | 2.3% | 1.9% | 2.0% | 1.4% | 1.3% | 1.1% | 1.1% | 1.2% | 1.0% | 0.9% | 1.0% | |
| -70.1% | -63.1% | -58.3% | -48.0% | -35.9% | -27.6% | -35.8% | -24.7% | -25.7% | -38.8% | -38.1% | -28.3% | -32.5% | |
| -3.0% | 4.2% | 2.6% | – | -2.3% | – | – | – | – | 0.2% | -0.1% | 0.1% | – | |
| -70.1% | -63.1% | -58.3% | -48.0% | -35.9% | -27.6% | -35.8% | -24.7% | -25.7% | -39.1% | -38.1% | -28.4% | -32.5% | |
| -64.2% | -57.5% | -53.3% | -43.7% | -31.7% | -24.1% | -32.4% | -21.6% | -22.7% | -35.4% | -35.0% | -25.3% | -29.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.